| Stage | DGX | % of rev | CDNA | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $3.1B | 100.00% | $264M | 100.00% | DGX ×11.74 |
| Gross profit | $1.0B | 33.65% | $229M | 86.75% | CDNA +53.1pp |
| Operating income | $479M | 15.47% | $113M | 42.90% | CDNA +27.4pp |
| Pre-tax income | $416M | 13.43% | $115M | 43.40% | CDNA +30.0pp |
| Net income | $326M | 10.53% | $111M | 41.92% | CDNA +31.4pp |
| Stage | DGX | CDNA | Gap · A − B |
|---|---|---|---|
| Revenue | $3.1B100.00% | $264M100.00% | DGX ×11.74 |
| Gross profit | 33.65%$1.0B | 86.75%$229M | CDNA +53.1pp |
| Operating income | 15.47%$479M | 42.90%$113M | CDNA +27.4pp |
| Pre-tax income | 13.43%$416M | 43.40%$115M | CDNA +30.0pp |
| Net income |
| 10.53%$326M |
| 41.92%$111M |
| CDNA +31.4pp |